Published in partnership with the

Logo

Club Jules Gonin

Tafluprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo

Akiyasu Kanamori, Maiko Naka, Masahide Fukuda, Makoto Nakamura and Akira Negi

View Related Documents

Abstract

Background  

To investigate whether tafluprost, which is a prostaglandin-related compound and an anti-glaucoma drug, has a direct anti-apoptotic effect in cultured retinal ganglion cells (RGCs) and rat RGCs in retinas with optic nerve crush (ONC).

Methods  

RGC-5 cells were induced to undergo apoptosis by a serum deprivation and by exogenous glutamate. The level of cell death with or without tafluprost was monitored by an XTT assay and by immunocytochemistry with activated caspase-3. Changes in intracellular calcium ([Ca2+]i) levels were measured with fluo-4 fluorescence. Rat RGCs were degenerated by ONC. After topical instillation of tafluprost for 7 and 14 days, the numbers of retrograde-labeled RGCs were counted. Retinal flatmounts were subjected to terminal dUTP nick end labeling (TUNEL) staining to detect apoptotic cells.

Results  

Tafluprost dose-dependently promoted RGC-5 cell viability with an optimum concentration of 3 μM (p = 0.006). Tafluprost significantly reduced caspase-3-positive cells and suppressed [Ca+2]i evoked by exogenous glutamate. The cGMP-dependent protein kinase inhibitor and KT-5823 partially blocked the rescue effect of tafluprost (p = 0.002). The survival rate of RGCs significantly increased in eyes treated with tafluprost (p = 0.01), and the prevalence of TUNEL-positive cells was significantly decreased 14 days after ONC (p < 0.001).

Conclusions  

These data suggest that tafluprost has an anti-apoptotic effect in RGCs.

Keywords  Retinal ganglion cell - Neuroprotection - Apoptosis - Tafluprost - Optic nerve crush

Fulltext Preview

Image of the first page of the fulltext document